Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (491)	5/23/2001 12:54:04 PM
From: The Dodgy Ticker	Read Replies (1) \| Respond to of 2243

Peregrine (old Techniclone) seems to be getting things in order for better times. Wilder liked the OXGN ASCO data, and the VTA technology is patented by PPHM and licensed to OXGN and SUPG. I have a position in it and recommend it as one to keep an eye on. Warm regards, Bob Wednesday May 23, 11:02 am Eastern Time Press Release Peregrine Pharmaceuticals Extends Its Agreement for the Development of Tumor Necrosis Therapy -TNT- in the People's Republic of China TUSTIN, Calif.--(BW HealthWire)--May 23, 2001--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM - news) today announced it has granted an extension to Cancer Therapeutics Inc. to allow Brilliance Pharmaceuticals Ltd. of Shanghai, China to continue to exclusively advance the commercialization of radiolabeled TNT in China. The TNT technology was licensed from Peregrine Pharmaceuticals to Brilliance Pharmaceuticals through an arrangement with Cancer Therapeutics (Los Angeles) in 1995. Peregrine will extend its marketing exclusivity arrangement with Cancer Therapeutics for the Chinese market in order for the Brilliance/Cancer Therapeutics joint venture to continue exclusive development and marketing of TNT-based products. Brilliance Pharmaceuticals has recently completed its definitive TNT Clinical Phase III trial for life-threatening cancers and is in the process of submitting an application for regulatory approval from the Chinese Drug Administration in Beijing. The application for regulatory approval was based upon clinical trials conducted at multiple centers in China for the past five years involving patients with various types of cancer such as lung, colorectal, brain, gastric, liver and sarcoma. Chen Shen, chief operations officer of Brilliance Pharmaceuticals, stated: ``We are very pleased with the extension of the agreement between Cancer Therapeutics Inc. and Peregrine Pharmaceuticals Inc. This will ensure that Brilliance Pharmaceuticals Ltd. maintains its exclusivity of the TNT product line in China well into the future. ``Marketing exclusivity will allow us to devote substantial resources into making TNT a significant cancer franchise well into the future. We are also looking forward to establishing a working relationship with Peregrine Pharmaceuticals as we finalize our commercialization efforts for a large-scale marketing launch of TNT.'' ``We are excited about continuing to work with Brilliance Pharmaceuticals to gain marketing approval of TNT for the treatment of all cancers in China. Peregrine's expertise in large-scale manufacturing and radiolabeling of antibodies will be valuable in assisting Brilliance Pharmaceuticals with the large-scale commercial launch of TNT in China,'' said Edward Legere, president and CEO of Peregrine. ``We are actively pursuing a collaboration with Brilliance Pharmaceuticals which will help in our own development plans for the TNT technology. We hope to gain valuable knowledge from the manufacturing scale-up and commercial launch of TNT in China which will be directly applicable to our own efforts in the U.S.'' With a population of approximately 1.3 billion, China is a vast market for cancer therapy. There are more than 7.3 million new cases and just more than 3 million deaths annually from cancer in the People's Republic of China according to statistical estimates of the American Cancer Society and the World Health Organization. Cancer became the main cause of death in China in 1996, ahead of heart disease, with an explosion in the number of cases of lung, breast, colon and rectal cancer, caused partly by the aging of China's population. China's per capital cancer incidence and deaths rank lower than the United States for many forms of cancer. The TNT technology is part of Peregrine Pharmaceuticals' collateral targeting agent technology portfolio. Collateral targeting agents are designed to bind to elements of tumors that are common to all solid tumors or are the product of tumor growth. TNT molecules bind to necrotic tissue that is formed by all solid tumors as they grow. The main advantage of collateral targeting agents is that one molecule could treat many different types of solid tumors thus greatly increasing the market potential of each compound developed. For example, Peregrine is currently developing Cotara(TM) in the United States for the treatment of brain cancer and has recently announced plans to move Cotara into a Phase III registration trial in the United States for this indication. The same Cotara agent is also being examined in the clinic for colorectal, pancreas, biliary, sarcoma and liver cancers. According to the American Cancer Society, there are more than 300,000 new cases of these types of cancer alone in the United States each year. Cotara may be able to treat many other types of solid tumors as well, and the company intends to continue to launch additional clinical studies to verify the efficacy of the drug in other solid tumor cancers. Peregrine Pharmaceuticals is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its ``collateral targeting technologies.'' These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attach solid tumors, without causing damage to surrounding healthy tissue. The company has three collateral targeting technologies: Tumor Necrosis Therapy, Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). The VTA agents are currently being developed in a joint venture with OXiGENE Inc. called Arcus Therapeutics LLC. The company also has a direct tumor targeting agent called Oncolym® for the treatment of advanced non-Hodgkin's B-cell Lymphoma. Oncolym has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym clinical trial programs as well as marketing. View Next 10 Messages \| Previous \| Next Bookmark this Subject Ignore this Person View SubjectMarks Enter symbols or keywords for search: QuotesStock TalkChartsNewsPeople Symbol Lookup Subject Titles Only Full Text This Subject Only Go to Top Terms of Use Got a comment, question or suggestion? Contact Silicon Investor.